Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-G-CSF for chemotherapy-induced neutropenia prevention in breast cancer
NCT06711523Phase 3Active, not recruiting
- Sponsor
- Kexing Biopharm
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pegfilgrastim in chemotherapy-induced neutropenia (CIN), sponsored by Kexing Biopharm. Started Jan 2025; status: active, not recruiting.
02
Drugs
pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT06711523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06711523.